Immunotherapeutic Approaches to the Management of Head and Neck Cancer.

Immunotherapeutic Approaches to the Management of Head and Neck Cancer.
Oncology (Williston Park). 2018 Dec 17;32(12):
Authors: Nan X, Gold KA, Cohen E
Abstract
The two programmed death 1 checkpoint inhibitors nivolumab and pembrolizumab are approved by the US Food and Drug Administration as second-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Based on the existing data, the effectiveness of these two drugs is similar in this setting. When choosing between them, the decision should be individualized and can be determined by patient and provider preferences, as well as scheduling. Testing for tumor programmed death ligand 1 (PD-L1) and human papillomavirus status is not required for use of these checkpoint inhibitors in the second-line setting, but the level of tumor PD-L1 expression can be useful for decision making in special situations. There are many ongoing trials that are studying immunotherapy as frontline treatment for recurrent or metastatic HNSCC, as well as trials combining immunotherapy with definitive chemoradiation in locally advanced disease. Based on the updated results of the KEYNOTE-048 trial, checkpoint inhibitors will likely be a part of first-line therapy in the near future.
PMID: 30632130 [PubMed - in process]

Source: Oncology (Williston Park, N.Y.) - December 17, 2018 Category: Cancer & Oncology Authors: Nan X, Gold KA, Cohen E Tags: Oncology (Williston Park) Source Type: research